[1] |
SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing.
Multiple pharmacological effects of Lingyang Ganmao Oral Liquid
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
|
[2] |
NING Xiao, GAO Guanghui, JIN Shaoming, LIU Tongtong, PEI Yusheng, CAO Jin.
Determination of erythromycin ointment content based on on-line column switching and liquid chromatography
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 152-155.
|
[3] |
ZHANG Zan, ZHANG Hui, HE Songhua, LUO Yi.
Four exogenously-polluted components in Tianwang Buxin pills analyzed via TLC and UPLC-QQQ-MS
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 156-162.
|
[4] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[5] |
LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo.
Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
|
[6] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[7] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[8] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[9] |
XIN Lingyi, YANG Yang, ZHU Jing, HE Na, ZHANG Jingmei, WANG Hangtian, CHEN Qinhua, YANG Guangyi.
Classification of anti-tumor active ingredients of Paridis Rhizoma and research progress in mechanisms of action
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 235-240.
|
[10] |
MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe.
Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng”
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32.
|
[11] |
ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan.
Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
|
[12] |
WANG Lyuyin, LI Yi, SUN Yue, HU Xinyue, ZHANG Hui, LI Jing, LIANG Chenggang.
Determination of sialic acid in recombinant human follicle stimulating hormone by high performance liquid chromatography with DMB derivatization
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 89-93.
|
[13] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[14] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[15] |
XIA Xudong, LI Meixia, SUN Yang, YANG Shengya.
Processes of remote inspection of pharmacovigilance for marketing authorization holders
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
|